General Information of Drug (ID: DMHDP9R)

Drug Name
PRS-211375 iv Drug Info
Synonyms
Cannabinor; Bicyclic cannabinoids, Pharmos; HU-308; PRS-211058; PRS-211096; PRS-211335; PRS-211359; PRS-211375; CB2-selective cannabinoid platform, Pharmos; Oral Cannabinor (pain), Pharmos; PRS-211375 (oral, pain), Pharmos; PRS-211375 (iv, inflammation/autoimmune disease), Pharmos
Indication
Disease Entry ICD 11 Status REF
Pain MG30-MG3Z Discontinued in Phase 2 [1]
Cross-matching ID
PubChem CID
9844711
TTD Drug ID
DMHDP9R

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Guanfacine extended release DMB1CZ8 Attention deficit hyperactivity disorder 6A05.Z Approved [3]
NABILONE DMVRYT2 Insomnia 7A00-7A0Z Approved [4]
GW-42004 DMY3KSU Lipid metabolism disorder 5C52.Z Phase 2 [5]
KHK-6188 DMF6CTI Neuropathic pain 8E43.0 Phase 2 [6]
LY-2828360 DMO8IEZ Pain MG30-MG3Z Phase 2 [6]
APD371 DM3XT5V Crohn disease DD70 Phase 2 [7]
S-777469 DMZGNOJ Atopic dermatitis EA80 Phase 2 [8]
842166X DMOV0AP Pain MG30-MG3Z Phase 2 [9]
Beta-caryophyllene DM7583A Pain MG30-MG3Z Phase 2 [10]
Vicasinabin DMF16CU Diabetic retinopathy 9B71.0 Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cannabinoid receptor 2 (CB2) TTMSFAW CNR2_HUMAN Agonist [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 746).
2 Brain CB2 Receptors: Implications for Neuropsychiatric Disorders. Pharmaceuticals (Basel) 2010 August; 3(8): 2517-2553.
3 Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory. Neurobiol Learn Mem. 2008 Sep;90(2):374-81.
4 Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
5 Company report (Gwpharm)
6 Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands. Current Medicinal Chemistry . 10/2013; 21(2).
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs. 2009 Mar;14(1):165-79.
9 The agonist binding mechanism of human CB2 receptor studied by molecular dynamics simulation, free energy calculation and 3D-QSAR studies. Yao Xue Xue Bao. 2013 Sep;48(9):1436-49.
10 The cannabinoid CB1 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. Eur Neuropsychopharmacol. 2014 Apr;24(4):608-20.
11 Clinical pipeline report, company report or official report of Roche